It touted the development as a key "milestone” in the production of CBD-loaded liposomes, as it now permits animal studies and at a later date, human clinical studies ─ both of which bring the product closer to market
Corporation () (OTCMKTS:INNPF) (FRA:IP4) said Friday that it would carry out a successful manufacturing demonstration of its liposome platform technology (LPT) to produce CBD-loaded liposomes under aseptic conditions with the Hebrew University, in Jerusalem.
The company touted the development as an “important milestone” in the production of CBD-loaded liposomes, as it now permits animal studies and at a later date, human clinical studies ─ both of which bring the product closer to market.
“This achievement supports studies on small and large animals, examining the therapeutic efficacy of Innocan's CBD-loaded LPT in relevant diseases,” said the company. Previous studies demonstrated the prolonged release of cannabidiol into the blood of mice and rats for at least three weeks after a single injection.
READ: InnoCan Pharma unveils its new user-friendly commercial website
The previous study led by Dr Ahuva Cern, a senior researcher in Professor Barenholz’s lab at the Hebrew University found significant amounts of CBD in the blood and muscles of mice up to 21 days after a single intramuscular injection of CBD using LPT. The same findings were also seen in rats, pointed out the company.
noted that these results are “substantial compared to other methods of CBD (including oral and inhaling), where CBD was found in the blood only for a period of up to 36 hours after a single administration.”
The company said the study results show that LPT, with only one or two injections per month, may relieve pain or other symptoms when using CBD. These results prepare the ground for future experiments to prove a lack of toxicity and the therapeutic potential of this formulation.
"Dozens of studies worldwide show the potential benefits of CBD in the human body in a wide range of diseases. A major problem with CBD is that it does not last in the body for a long time, which lessens the ability to unfold the positive value,” said InnoCan Pharma founder CEO Iris Bincovich.
“Our previous studies with mice and rats indicated that our technology to embed CBD into liposomes, LPT, can possibly extend the timeframe from hours to weeks. The ability to manufacture CBD-loaded liposomes in an aseptic way is a milestone for our company because it opens the door to a wide range of applications and enables us to go ahead with our studies with small and large animals and, as a final subject, humans.”
Dr Ahuva Cern, the project manager in Professor Barenholz's laboratory at the Hebrew University stated: "We succeeded in manufacturing CBD-loaded liposomes under aseptic conditions. Those liposomes loaded with CBD were found to be sterile and conform to the pyrogenicity limits.”
“This achievement is a 'must' step as we are looking forward to large scale production and later commercial size production."
InnoCan, through its wholly-owned Israeli subsidiary InnoCan Pharma Ltd, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol, or CBD.
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive
